Waldencast plc operates as a global multi-brand beauty and wellness platform built around Obagi Medical and Milk Makeup. News about WALD commonly covers brand-level product launches, physician-dispensed skincare, cosmetics, suncare, and aesthetic offerings, including Obagi's advanced skincare products and Obagi® saypha® MagIQ™ hyaluronic acid filler.
Company updates also include quarterly and annual financial results, segment performance, channel and distribution developments, clinical-evidence collaborations for aesthetic products, supply-chain and credit-facility actions, and governance or reporting matters tied to financial restatements, internal control over financial reporting, and regulatory review.
Obagi Medical (WALD) launched Nu-Cil® BioStim™ Scalp Serum on October 8, 2025, a leave-in scalp serum priced at $125 and sold on Obagi.com.
The product uses a BioStim™ Complex with biotin, amino acids, peptides, 18 nutrients, B vitamins, and phytoactives. In a six-month, double-blind clinical study the serum showed: 74% reduction in dry fallen hair at 3 months, 2.8% increase in hair count per cm² at 3 months, 52% hair volume improvement in under 6 months, and up to 97% decrease in dry fallen hair in less than six months, with some benefits visible after two weeks.
Waldencast (NASDAQ: WALD) has received FDA approval for Obagi® saypha® MagIQ™, an injectable hyaluronic acid gel under the Obagi Medical brand. This marks the company's entry into the U.S. HA dermal filler market, with launch planned for 2026. The product utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix for natural-looking results.
The approval follows a successful pivotal study of 270 patients over 48 weeks, meeting primary and secondary endpoints. This expansion is expected to double Obagi Medical's total addressable market to $4.2 billion by 2029. The product, developed by Croma-Pharma GmbH, will be followed by additional products in the saypha® line, including Obagi® saypha® ChIQ™ pending FDA approval.
Waldencast (NASDAQ: WALD), a global beauty platform, reported mixed H1 2025 results with notable developments. Obagi Medical achieved double-digit growth in core strategic channels and completed the Novaestiq acquisition, doubling its U.S. addressable market. Milk Makeup delivered high-20s growth in U.S. retail sales in Q2, driven by Ulta Beauty expansion and Amazon Premium Beauty launch.
The company revised its FY 2025 guidance to low to mid-single digit revenue growth with adjusted EBITDA margins in the low to mid-teens. Waldencast announced a strategic review to maximize shareholder value and postponed H1 2025 earnings release for additional analysis. Key challenges included international market softness, retailer destocking, and out-of-stock issues, though improving.
Waldencast (NASDAQ: WALD) has announced the acquisition of Novaestiq Corp. and U.S. rights to the Saypha® hyaluronic acid injectable gel line. The strategic move expands Obagi Medical's portfolio beyond skincare into the dermal filler market, effectively doubling its addressable market to $4.2 billion by 2029.
The transaction terms include cash payment, ongoing royalties, and potential issuance of Waldencast class A shares representing approximately 7% of fully diluted shares, contingent on FDA approval and revenue milestones of $100 million and $200 million. The Saypha® line, currently pending FDA approval, is globally recognized and manufactured in Austria with distribution in over 80 countries.
This acquisition positions Obagi Medical to become a leading dermatological mega brand by combining medical-grade skincare with aesthetic treatments, supported by extensive clinical studies particularly focused on diverse skin types.
Waldencast (NASDAQ: WALD) has scheduled its First Quarter Fiscal 2025 earnings conference call and webcast for May 14, 2025, at 8:30am ET. The company will release its Q1 FY2025 financial results on May 13, 2025 after U.S. market close. Investors and analysts can participate by dialing (877) 704-4453, or (201) 389-0920 for international callers. A slide presentation will accompany the webcast, accessible at ir.waldencast.com, with a replay available on the website for 90 days.
Obagi Medical, a subsidiary of Waldencast plc (NASDAQ: WALD) and the fastest-growing professional skincare brand in the U.S. in 2024, has launched its new Retinol + PHA Refining Night Cream. The $135 product combines Entrapped Retinol with Polyhydroxy Acid (PHA) Gluconolactone in a slow-release formula.
The clinical study demonstrated significant results after four weeks:
- 29% increase in skin smoothness
- 10% improvement in skin tone evenness
- 90% of users reported visibly smoother skin texture
- 90% observed reduced blemish appearance
The formula includes eight additional ingredients including Sodium Hyaluronate, Vitamin E, Squalane, and Glycerin. The product will be available through professional channels and on Obagi.com starting May 5, 2025.
Waldencast (NASDAQ: WALD) reported strong Q4 2024 and full-year financial results. Q4 highlights include net revenue of $72.1 million (29.4% growth), and Adjusted EBITDA of $11.2 million (doubled from Q4 2023). Full-year 2024 delivered net revenue of $273.9 million with 27.5% growth and $40.3 million in Adjusted EBITDA.
Key developments:
- Obagi Medical emerged as the fastest-growing professional skincare brand among top 10 in US for 2024
- Milk Makeup secured expansion to 600+ Ulta Beauty locations for Spring 2025
- Company secured new $205 million credit facility
Brand Performance: Obagi Medical Q4 revenue reached $42.2 million (27.7% growth) with $9.8 million Adjusted EBITDA. Milk Makeup achieved $29.9 million revenue (31.9% growth) with $4.8 million Adjusted EBITDA.
2025 Outlook: Company projects mid-teens revenue growth and Adjusted EBITDA margin expansion into mid-to-high teens, with growth acceleration expected throughout the year.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has scheduled its Fourth Quarter and Fiscal Year 2024 earnings release and conference call. The company will release its financial results on March 18, 2025 after U.S. market close, followed by a conference call with management on March 19, 2025 at 8:30am ET.
Interested investors and analysts can participate by dialing (877) 704-4453, or (201) 389-0920 for international callers. The event will include a slide presentation and will be webcast live at ir.waldencast.com, with the replay remaining available for 90 days.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit on February 26, 2025, in New York. Michel Brousset, Founder and CEO, will engage in a fireside chat presentation at 2:45 p.m. EST and conduct investor meetings throughout the day. The presentation will be available via live webcast and replay on Waldencast's Investor Relations website.